Psivida closer to Nasdaq listing
Thursday, 20 January, 2005
Nanotechnology company Psivida (ASX:PSD) is to join a small band of Australian biotechs on the US Nasdaq market, announcing today it had filed a registration statement with the US Securities and Exchange Commission in relation to its planned listing of American Depositary Shares (ADSs).
Psivida expects its ADSs to begin trading before the end of January.
"The Nasdaq listing will enable a range of domestic US institutions whose investment guidelines are restricted to US securities, to trade our shares as a US ADR security," said CEO Gavin Rezos in an interview last year. "This ADR listing also provides potential representation of Psivida in US-based nanotechnology indices,"
Psivida currently trades on the ASX, on Frankfurt's XETRA and in the UK's OFEX International Market Service (IMS). Melbourne's Prana Biotechnology (ASX:PBT, NASDAQ:PRAN) and Genetic Technologies (ASX:GTX, NASDAQ:GNTLY) are also listed on Nasdaq.
Oxytocin analogue treats chronic abdominal pain
Researchers have developed a new class of oral painkillers to suppress chronic abdominal pain,...
'Low-risk' antibiotic linked to rise of dangerous superbug
A new study has challenged the long-held belief that rifaximin — commonly prescribed to...
Robotic hand helps cultivate baby corals for reef restoration
The soft robotic hand could revolutionise the delicate, labour-intensive process of cultivating...
